Logo image of LCI

LANNETT CO INC (LCI) Stock Fundamental Analysis

NYSE:LCI - US5160122009 - Common Stock

0.6855 USD
+0.03 (+3.86%)
Last: 4/19/2023, 8:06:04 PM
Fundamental Rating

1

Overall LCI gets a fundamental rating of 1 out of 10. We evaluated LCI against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of LCI have multiple concerns. LCI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LCI had negative earnings in the past year.
In the past year LCI has reported a negative cash flow from operations.
In the past 5 years LCI reported 4 times negative net income.
Of the past 5 years LCI 4 years had a positive operating cash flow.
LCI Yearly Net Income VS EBIT VS OCF VS FCFLCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M -200M -300M

1.2 Ratios

LCI has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LCI Yearly ROA, ROE, ROICLCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 1K

1.3 Margins

With a Gross Margin value of 12.26%, LCI perfoms like the industry average, outperforming 52.97% of the companies in the same industry.
In the last couple of years the Gross Margin of LCI has declined.
LCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 12.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-36.01%
GM growth 5Y-27.28%
LCI Yearly Profit, Operating, Gross MarginsLCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

LCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LCI has more shares outstanding
LCI has a worse debt/assets ratio than last year.
LCI Yearly Shares OutstandingLCI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
LCI Yearly Total Debt VS Total AssetsLCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -1.51, we must say that LCI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of LCI (-1.51) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.51
ROIC/WACCN/A
WACC4.16%
LCI Yearly LT Debt VS Equity VS FCFLCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 2.23 indicates that LCI has no problem at all paying its short term obligations.
LCI has a Current ratio of 2.23. This is in the lower half of the industry: LCI underperforms 63.01% of its industry peers.
LCI has a Quick Ratio of 1.39. This is a normal value and indicates that LCI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.39, LCI is doing worse than 68.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 1.39
LCI Yearly Current Assets VS Current LiabilitesLCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for LCI have decreased strongly by -129.18% in the last year.
LCI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -24.09%.
The Revenue for LCI have been decreasing by -11.78% on average. This is quite bad
EPS 1Y (TTM)-129.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.82%
Revenue 1Y (TTM)-24.09%
Revenue growth 3Y-19.6%
Revenue growth 5Y-11.78%
Sales Q2Q%-6.49%

3.2 Future

LCI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.51% yearly.
The Revenue is expected to decrease by -0.68% on average over the next years.
EPS Next Y-3.01%
EPS Next 2Y4.42%
EPS Next 3Y8.51%
EPS Next 5YN/A
Revenue Next Year-11.78%
Revenue Next 2Y-5.15%
Revenue Next 3Y-0.68%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LCI Yearly Revenue VS EstimatesLCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
LCI Yearly EPS VS EstimatesLCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LCI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LCI Price Earnings VS Forward Price EarningsLCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LCI Per share dataLCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.42%
EPS Next 3Y8.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LCI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LANNETT CO INC

NYSE:LCI (4/19/2023, 8:06:04 PM)

0.6855

+0.03 (+3.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-01 2023-02-01/amc
Earnings (Next)05-02 2023-05-02/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners133.44%
Ins Owner Change0%
Market Cap7.38M
Analysts46.67
Price Target4.08 (495.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.25%
Min EPS beat(2)8.61%
Max EPS beat(2)17.89%
EPS beat(4)4
Avg EPS beat(4)9.07%
Min EPS beat(4)4.48%
Max EPS beat(4)17.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)9.34%
Min Revenue beat(2)8.96%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)2.45%
Min Revenue beat(4)-7.25%
Max Revenue beat(4)9.72%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)300%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-294.94%
EPS NY rev (1m)0%
EPS NY rev (3m)-283.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.44
EYN/A
EPS(NY)-5.49
Fwd EYN/A
FCF(TTM)-5.56
FCFYN/A
OCF(TTM)-4.78
OCFYN/A
SpS28.66
BVpS-29
TBVpS-31.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 12.26%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-36.01%
GM growth 5Y-27.28%
F-Score2
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.23
Quick Ratio 1.39
Altman-Z -1.51
F-Score2
WACC4.16%
ROIC/WACCN/A
Cap/Depr(3y)48.49%
Cap/Depr(5y)64.83%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-129.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.82%
EPS Next Y-3.01%
EPS Next 2Y4.42%
EPS Next 3Y8.51%
EPS Next 5YN/A
Revenue 1Y (TTM)-24.09%
Revenue growth 3Y-19.6%
Revenue growth 5Y-11.78%
Sales Q2Q%-6.49%
Revenue Next Year-11.78%
Revenue Next 2Y-5.15%
Revenue Next 3Y-0.68%
Revenue Next 5YN/A
EBIT growth 1Y-129.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year101.64%
EBIT Next 3Y40.89%
EBIT Next 5YN/A
FCF growth 1Y-354.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-217.84%
OCF growth 3YN/A
OCF growth 5YN/A